ALBRIOZA Commercial Launch

Framework to Select Future Indications Rigorous process in place to determine next indication for AMX0035 Clear unmet need Strong scientific rationale Biomarker evidence Existing and robust understanding of the natural history of the disease Potential to move directly into a Phase 3 pivotal trial Adjacencies and synergies with ALS Interest and support from KOLS and advocacy groups AMYLYX 28

View entire presentation